>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息：
西达本胺联合顺铂对三阴乳腺癌细胞株 MDA-MB-231的体外抗增殖作用及其机制的研究
作者：项丹1 2  姜藻1  顾晓怡1 
单位：1. 东南大学附属中大医院 肿瘤中心, 江苏 南京 210009;
2. 东南大学环境医学工程 教育部重点实验室, 江苏 南京 210009
关键词：三阴乳腺癌 西达本胺 顺铂 组蛋白脱乙酰基酶类 基因 ERCC1 
分类号：R737.9;R979.1
出版年·卷·期（页码）：2013·32·第三期（283-288）
摘要：

目的:探讨西达本胺联合顺铂对三阴乳腺癌细胞株MDA-MB-231的抑制作用及其可能的分子机制。方法:单独及联合给药后采用MTT法测定MDA-MB-231细胞的增殖,流式细胞仪(FCM)检测细胞凋亡率,Western blotting法分析乙酰化组蛋白H3及HDAC3的表达水平,荧光定量PCR检测ERCC1表达水平。结果:MTT法检测发现,西达本胺单药和顺铂单药在体外对细胞株MDA-MB-231增殖都有一定的抑制作用,且呈浓度、时间依赖性;联合用药可起到协同效应。西达本胺可抑制MDA-MB-231细胞株HDAC3的表达,提高组蛋白H3的乙酰化水平。联合顺铂起到协同效应的分子机制主要是降低细胞株ERCC1的表达水平。结论:西达本胺联合顺铂在体外能协同抑制三阴乳腺癌细胞株MDA-MB-231的增殖。

Objective: To explore the chidamide in combination with cisplatin on three negative breast cancer cells MDA-MB-231 inhibition and its possible molecular mechanism. Methods: The separate and combined administration with MTT method for the determination of MDA-MB-231 cell proliferation,flow cytometry(FCM) examination apoptosis rate,analysis of Western blotting acetylation of histone H3 and HDAC3 expression levels,fluorescence quantitative PCR detection of ERCCl expression level. Results: The detection of MTT showed that chidamide monotherapy and cisplatin monotherapy for in vitro cell line MDA-MB-231 value has certain inhibitory action in a dose-and time-dependent manner.Combined medication can play a synergistic effect.Chidamide can inhibit MDA-MB-231 cell HDAC3 expression,increased histone H3 acetylation levels. The synergistic effect combined with cisplatin of molecular mechanism is to decrease the expression of ERCC1. Conclusion: Chidamide in combination with cisplatin in vitro may synergistically inhibit the proliferation of TNBC cell lines MDA-MB-231.
参考文献：

[1] HU Z,FAN C,OH D S,et al.The molecular portraits of breast tumors are conserved across microarray platforms[J].BMC Genomics,2006,(7):96.
[2] BERTUCCI F,FINETTI P,CERVERA N,et al.How basal are triple-negative breast cancers？ [J].Int J Cancer,2008,123(1):236-240.
[3] WILLIAM J,IRVIN Jr,LISA A.What is triple-negative breast cancer？ [J].Eur J Cancer,2008,44(18):2799-2805.
[4] DIALLO-DANEBROCK R,TING E,GLUZ O,et al.Prognostic and predictive impact of protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy[J].Clin Cancer Res,2007,13(2):488-497.
[5] CAREY L A,PEROU C M,LIVASY C A,et al.Race,breast cancer subtypes,and survival in the Carolina breast cancer study[J].JAMA,2006,295(21):2492-2502.
[6] DIALLO-DANEBROCK R,TING E,GLUZ O,et al.Prognostic and predictive impact of protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy[J].Clin Cancer Res,2007,13(2):488-497.
[7] BAUER K R,BROWN M,CRESS R D,et al.Descriptive analysis of estrogen receptor(ER)-negative,progesterone receptor(PR)-negative,and HER2-negative invasive breast cancer,the so-called triple-negative phenotype:a population-based study from the California Cancer Registry[J].Cance,2007,109(9):1721-1728.
[8] MINUCCI S,PELICEI P G.Histone deacetylase inhibitors and the promise of epigenetic(and more) treatments for cancer[J].Nat Rev Cancer,2006,6(1):38-51.
[9] 尹子卉,吴仲闻,兰玉坤,等.新型抗肿瘤组蛋白去乙酰化酶抑制剂西达本胺的合成[J].中国新药杂志,2004,13(6):536-538.
[10] 郑杰.肿瘤的细胞与分子生物学[M].上海:上海科学技术出版社,2011:249-251.
[11] 陈佳,周武庆,陈浩,等.西达本胺对恶性黑色素瘤细胞系A375的体外抗增殖作用[J].中华皮肤科杂志,2009,42(4):255-258.
[12] 程宏,王璇琳,赵丽晶,等.西达本胺对人前列腺癌DU145及PC3细胞凋亡的影响[J].生物技术通讯,2012,10(4):176-179.
[13] 何向明,李苏宜,刘琳,等.西达本胺对结肠癌LoVo细胞增殖抑制的体外研究[J].肿瘤学杂志,2009,15(4):310-313.
[14] 李艳莹,王艳芳.西达本胺对人B淋巴细胞株的作用及其机制研究[J].中国实验血液学杂志,2012,20(4):893-899.
[15] 周珊,姜藻,顾晓怡.西达本胺对胃癌SGC-7901细胞增殖、凋亡及Notch1、Sirt1基因表达的影响研究[J].东南大学学报:医学版,2012,31(3):273-276.
[16] NING Z Q,LI Z B,NEWMAN M J,et al.Chidamide(CSO55/HBI-8000):a new histone deacetylase inhibitor of yhe benzamide class with antitumor activity and the ability to enhance immune cell-mediated humor cell cytotoxicity[J].Cancer Chemother Pharmacol,2012,69(4):901-909.
[17] LIU L,CHEN B,QIN S,et al.Anover histone deacetylase inhibitor chidamide induse apoptosis of hum colou cancer cells[J].Biochem Biophys Commun,2010,292(2):190-195.
[18] ALTAHA R,IAANG X,YU J J,et al.Excision repair cross complementing—group1:gene expression and platinum resistance [J].Int J Mol Med,2004,14:959-970.
[19] 成红艳,陈宝安,孙新臣,等,ERCC1、XRCC1单核苷酸多态性与非小细胞肺癌铂类药物化疗预后关系的研究[J].东南大学学报:医学版,2011,30(5):717-721.
[20] EBPG Expert Group on Renal Transplantation.European best practice guidelines for renal transplantation[J].Nephrol Dial Transplant,2002,17(4):34-39.
服务与反馈：
【文章下载】【发表评论】【查看评论】【加入收藏】
提示：您还未登录，请登录！点此登录
您是第 414362 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话：025-83272481 83272483
电子邮件： bjb@pub.seu.edu.cn

苏ICP备09058364